Opus Genetics officer proposes $56.1K share sale

The shares are to be sold automatically under a previously adopted plan to satisfy tax withholding obligations arising from RSU vesting and settlement.

Rhea-AI Filing Summary

Opus Genetics, Inc. officer Robert E. Gagnon reported a proposed sale of 14,000 common shares through Jefferies LLC, with an aggregate market value of $56,140.00 and an approximate sale date of October 23, 2026. The company requires the shares to be sold automatically under a previously adopted 10b5-1 Sales Plan dated April 30, 2026, to satisfy tax withholding obligations from an RSU award’s vesting and settlement. The transaction is not a discretionary trade by Gagnon.

Key Figures

Proposed sale: 14,000 common shares Aggregate market value: $56,140.00 Shares sold July 23, 2026: 7,783 shares +3 more

6 metrics

Proposed sale 14,000 common shares Approximate sale date October 23, 2026

Aggregate market value $56,140.00 Proposed sale

Shares sold July 23, 2026 7,783 shares Sales during the prior three months

Gross proceeds July 23, 2026 $22,941.72 Sales during the prior three months

Shares sold September 3, 2026 28,000 shares Sales during the prior three months

Gross proceeds September 3, 2026 $127,212.40 Sales during the prior three months

Key Terms

10b5-1 Sales Plan, Vested Restricted Stock Units, tax withholding obligations

3 terms

10b5-1 Sales Plan financial

"previously adopted 10b5-1 Sales Plan"

A 10b5-1 sales plan is a written, prearranged schedule that company insiders use to buy or sell their employer’s stock under a U.S. securities rule, so trades occur automatically at set times or prices regardless of later private information. It matters to investors because it reduces the risk of insider-trading accusations and signals that certain insider trades were planned ahead—like putting transactions on autopilot—while still affecting share supply and market confidence.

Vested Restricted Stock Units financial

"Vested Restricted Stock Units"

tax withholding obligations financial

"satisfy tax withholding obligations"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IRD shares does Opus Genetics officer Robert E. Gagnon plan to sell?

Robert E. Gagnon reported a proposed sale of 14,000 common shares, with an aggregate market value of $56,140.00. The approximate sale date is October 23, 2026, and Jefferies LLC is listed as the broker.

Why is Robert E. Gagnon’s proposed IRD share sale automatic?

The company requires the shares to be sold automatically to satisfy tax withholding obligations arising from an RSU award’s vesting and settlement. The sale is under a previously adopted 10b5-1 Sales Plan dated April 30, 2026, and is not a discretionary trade by Gagnon.

What shares did Robert E. Gagnon sell in the three months before the proposed IRD sale?

The reported prior sales were 7,783 shares on July 23, 2026, for $22,941.72, and 28,000 shares on September 3, 2026, for $127,212.40.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/23/2026 - 04:05 PM EDT Accepted by SEC EDGAR 10/23/2026 - 04:04 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001504983
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Opus Genetics, Inc.
SEC File Number	001-34079
Address of Issuer	8 DAVIS DRIVE SUITE 220 DURHAM NORTH CAROLINA 27713
Phone	(984) 884-6030
Name of Person for Whose Account the Securities are To Be Sold	Gagnon Robert E.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave New York NY 10022	14000	56140.00	83200000	10/23/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/22/2026	Vested Restricted Stock Units	Opus Genetics, Inc.			14000	01/22/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Robert E Gagnon 8 Davis Drive Ste. 220 Durham NC 27709	Opus Genetics, Inc.	07/23/2026	7783	22941.72
Robert E Gagnon 8 Davis Drive Ste. 220 Durham NC 27709	Opus Genetics, Inc.	09/03/2026	28000	127212.40

144: Remarks and Signature

Remarks	Pursuant to a previously adopted 10b5-1 Sales Plan dated 4/30/2026; shares to be sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a RSU award. This transaction will not represent a discretionary trade by the Reporting Person.
Date of Notice	10/23/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	04/30/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Robert Gagnon
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)